Yumanity Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

BOSTON, Jan. 6, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX) announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference. The presentation will be available on-demand starting January 11, 2021, at 6:00 AM EST on the conference portal and Yumanity's website.

Yumanity is focused on developing innovative therapies for neurodegenerative diseases, with its lead candidate, YTX-7739, in Phase 1 clinical trials for Parkinson’s disease. The company also targets other conditions such as ALS and Alzheimer’s.

BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Paulash Mohsen, Chief Business Officer, will present at the H.C. Wainwright Virtual BioConnect Conference.

The presentation will be available on-demand via the conference portal and through the Company's website at yumanity.com/events beginning January 11, 2021 starting at 6:00am EST.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on dementia with Lewy bodies, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease.

For more information, please visit www.yumanity.com.

Contacts
Investors:
Burns McClellan, Inc.
John Grimaldi
jgrimaldi@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006

 

FAQ

What is Yumanity Therapeutics presenting at the H.C. Wainwright Virtual BioConnect Conference?

Yumanity Therapeutics will have a presentation by Chief Business Officer Paulash Mohsen, available on-demand starting January 11, 2021.

When can I watch Yumanity Therapeutics' presentation at the conference?

The presentation will be available on-demand from January 11, 2021, at 6:00 AM EST.

What is Yumanity Therapeutics' most advanced product candidate?

Yumanity Therapeutics' lead candidate is YTX-7739, currently in Phase 1 clinical development for Parkinson’s disease.

What conditions is Yumanity Therapeutics targeting?

Yumanity Therapeutics is targeting neurodegenerative diseases, including ALS, Alzheimer’s disease, and dementia with Lewy bodies.

What is the stock symbol for Yumanity Therapeutics?

The stock symbol for Yumanity Therapeutics is YMTX.